Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2019 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium

AUSTIN, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
August 06, 2019 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights

FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from Arginase 1 Deficiency...
July 24, 2019 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency

AUSTIN, Texas, July 24, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
June 03, 2019 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency

Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas, June 03, 2019 (GLOBE NEWSWIRE) -- Aeglea...
May 30, 2019 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences

AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
May 07, 2019 07:45 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights

Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from...
April 07, 2019 19:15 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilarginase Clinically Impactful Responses Captured by Mobility and Adaptive Behavior Assessments Management to Host...
April 01, 2019 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

AUSTIN, Texas, April 01, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
March 28, 2019 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences

AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
March 07, 2019 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights

On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with Pegzilarginase Cancer...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right